Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma - Related Studies

Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)

This study is currently recruiting participants.

Verified December 2012 by Duke University

Study NCT01108445 Information provided by Duke University

First Received on April 20, 2010. Last Updated on December 11, 2012 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Additional conditions recognized in this trial

Carcinoma
Carcinoma, Renal Cell

More general conditions related to this trial

Interventions listed in this trial

Everolimus
Sunitinib

Additional drug interventions recognized in this trial

Sirolimus

More general drug interventions related to this trial

Sponsors listed in this trial

Duke University
Novartis
Pfizer